Table 1

Summary of clinical trials targeting geographic atrophy

TargetTreatmentClinical trial numberCompanyStatus of clinical trials
Anti-inflammatoryEculizumabNCT00935883Alexion Pharmaceuticals (Cheshire, Connecticut, USA)Completed phase II
SirolimusNCT00766649National Eye Institute (Bethesda, Maryland, USA)Completed phase I/II
LampalizumabNCT02247479Hoffmann-LaRoche (Basel, Switzerland)
Roche (Basel, Switzerland)
Phase III currently recruiting
ARC-1905NCT00950638Ophthotech (Princeton, New Jersey, USA)Completed phase I
Glatiramer acetateNCT00541333The New York Eye & Ear Infirmary (New York, New York, USA)Phase I suspended participant recruitment
AntioxidantsAREDS2NCT00345176National Eye Institute (Bethesda, Maryland, USA)Phase III completed
OT-551NCT00306488National Eye Institute (Bethesda, Maryland, USA)
Other Pharmaceuticals (Exton, Pennsylvania, USA)
Phase II completed
Visual cycle inhibitorsFenretinideNCT00429936Sirion Therapeutics, Inc. (Tampa, Florida, USA)Phase II completed
Emixustat Hydrochloride (ACU-4429)NCT01802866Acucela Inc. (Seattle, Washington, USA)Phase II/III ongoing
ALK-001NCT02230228Alkeus Pharmaceuticals, Inc. (Boston, Massachusetts, USA)Phase I completed
Amyloid betaMRZ-99030NCT01714960Merz Pharmaceuticals GmbH (Dessau-Roßlau, Germany)Phase I completed
RN6GNCT01003691Pfizer (New York, New York, USA)Phase I completed
GSK933776NCT01342926GlaxoSmithKline (Brentford, UK)Phase II ongoing
Choroidal perfusionMC-1101NCT02127463MacuCLEAR, Inc. (Plano, Texas, USA)Phase II/III currently recruiting
Stem cell therapyMA09-hRPENCT01344993Ocata Therapeutics (Marlborough, Massachusetts, USA)Phase I/II currently recruiting
MA09-hRPENCT01674829CHABiotech Co., Ltd (Seoul, South Korea)Phase I/IIa currently recruiting
HuCNS-SCNCT01632527StemCells, Inc. (Newark, California, USA)Phase I/II ongoing
  • AREDS2, Age Related Eye Disease Study 2; hRPE, retinal pigment epithelial; HuCNS-SC, human central nervous system stem cells.